Compared to conventional EGFRvIII-specific CAR-T cells, EGFRvIII-P2A-PD1CD28 CAR-T cells exhibited enhanced functionality and anti-tumor effects against PD-L1+/EGFRvIII+ tumors. This evidence concerns the gene CD274 and neoplasm.